Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal heparin in CAPD.

E Gries1, N Graben, K D Bock

  • 1Dept. of Clinical Chemistry, University of Essen, FRG.

Life Support Systems : the Journal of the European Society for Artificial Organs
|January 1, 1985
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanoscale electronic order in iron pnictides.

Physical review letters·2010
Same author

[The status of medical research].

Versicherungsmedizin·2009
Same author

75As NMR studies of superconducting LaFeAsO0.9F0.1.

Physical review letters·2008
Same author

Transient or occult HIV infections may occur more frequently than progressive infections: changing the paradigm about HIV persistence.

Archives of virology. Supplementum·2005
Same author

Pre-Medline evidence of stroke mortality trends.

Lancet (London, England)·2003
Same author

Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.

Journal of human virology·2001
Same journal

Biocompatibility testing of membrane plasmapheresis devices.

Life support systems : the journal of the European Society for Artificial Organs·1987
Same journal

The relationship between biocompatibility and interleukin-1.

Life support systems : the journal of the European Society for Artificial Organs·1987
Same journal

Complement activation and leucopenia on cellulosic haemodialyzers: influence of the membrane area and role of hydroxyl moieties.

Life support systems : the journal of the European Society for Artificial Organs·1987
Same journal

Side effects and mortality associated with plasma exchange: a three year experience with a regional register.

Life support systems : the journal of the European Society for Artificial Organs·1987
Same journal

Dynamic cardiomyoplasty: a new approach to assist chronic myocardial failure.

Life support systems : the journal of the European Society for Artificial Organs·1987
Same journal

Counterpulsation in atrio-aortic bypass: theoretical and experimental aspects.

Life support systems : the journal of the European Society for Artificial Organs·1987
See all related articles

Intraperitoneal heparin in continuous ambulatory peritoneal dialysis (CAPD) largely remains in the peritoneal cavity. Systemic heparin activity is minimal, with no significant impact on clotting times.

Area of Science:

  • Nephrology
  • Pharmacology
  • Biochemistry

Background:

  • Continuous ambulatory peritoneal dialysis (CAPD) is a treatment for kidney failure.
  • Heparin is often used to prevent clotting in dialysis circuits.
  • Understanding heparin's systemic effects during CAPD is crucial for patient safety.

Purpose of the Study:

  • To investigate the systemic effects of intraperitoneally administered heparin in CAPD patients.
  • To quantify heparin levels and activity in both the peritoneal fluid and plasma.

Main Methods:

  • Six CAPD patients received 5000 U of heparin intraperitoneally.
  • Heparin concentrations in dialysate were measured serially.
  • Plasma anti-IIa and anti-Xa activities were assessed.

Related Experiment Videos

  • Activated partial thromboplastin time was monitored.

    • Main Results:

    • Intraperitoneal heparin levels decreased by 1825 U over 4 hours.
    • Significant increases in plasma anti-IIa (4 hrs) and anti-Xa (2 & 4 hrs) activities were observed (p <= 0.05).
    • Maximum plasma heparin activity was low (0.015 U/ml anti-IIa, 0.024 U/ml anti-Xa).
    • No increase in activated partial thromboplastin time was noted.

    Conclusions:

    • Heparin administered intraperitoneally during CAPD is primarily localized to the peritoneal cavity.
    • Systemic absorption and anticoagulant effect are minimal compared to subcutaneous administration.
    • The use of heparin in CAPD appears to have a localized effect, minimizing systemic risks.